Skip to main
BTMD

Biote Corp (BTMD) Stock Forecast & Price Target

Biote Corp (BTMD) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Biote is at risk of losing market share to competitors if they are unable to effectively defend or protect their patents, trademarks, trade secrets, and other intellectual property. Additionally, closures and disruptions caused by pandemics could impact the company's operations and revenue. However, as a financial analyst, I believe Biote's growth and success in providing personalized hormone optimization solutions to medical practitioners and their patients makes it a strong investment opportunity despite these potential risks.

Bears say

Biote is facing multiple challenges including declining revenue, potential regulatory fines, data security breaches, and competition. The company has had lower than expected revenue and AEBITDA, leading to decreased gross margin and challenges with acquisitions and managing attrition. The company also faces potential risks related to rising interest rates, inflation, and political uncertainty.

Biote Corp (BTMD) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biote Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biote Corp (BTMD) Forecast

Analysts have given Biote Corp (BTMD) a Buy based on their latest research and market trends.

According to 3 analysts, Biote Corp (BTMD) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biote Corp (BTMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.